SCHEMBL23574227

SCHEMBL23574227

CC(C)(C)OC(=O)NCC(CNC(=O)OC(C)(C)C)COCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.59
SYK P43405 1/20 0.59
CTSS P25774 4/20 0.59
PPARG P37231 1/20 0.54
KLK7 P49862 2/20 0.49
KLK5 Q9Y337 2/20 0.49
IDO1 P14902 1/20 0.49
ATM Q13315 1/20 0.47
CTSK P43235 2/20 0.45
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA7 P43166 1/20 0.45
CA14 Q9ULX7 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43
AKT1 P31749 2/20 0.43
PSMB11 A5LHX3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4744957 0.88 PPARA (0.58) PPARASYKCTSSPPARGKLK7
SCHEMBL397978 0.88 PPARA (0.58) PPARASYKCTSSPPARGKLK7
SCHEMBL29295304 0.88 PPARA (0.58) PPARASYKCTSSPPARGKLK7
SCHEMBL22018391 0.87 PPARA (0.57) PPARASYKCTSSPPARGKLK7
SCHEMBL21128729 0.87 PPARA (0.57) PPARASYKCTSSPPARGKLK7
SCHEMBL27252490 0.87 SYK (0.57) PPARASYKCTSSPPARGKLK7
SCHEMBL28387647 0.86 PPARA (0.56) PPARASYKCTSSPPARGKLK7
SCHEMBL28578904 0.85 PPARA (0.55) PPARASYKCTSSPPARGKLK7
SCHEMBL28915565 0.85 PPARA (0.55) PPARASYKCTSSPPARGKLK7
SCHEMBL28578906 0.85 PPARA (0.55) PPARASYKCTSSPPARGKLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4371982-A2 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX Pharmaceuticals, Inc. (US) 2024-05-22 EP disclosed
EP-3583096-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2024-03-27 EP disclosed
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 US disclosed
US-20210198316-A9 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-07-01 US disclosed
CN-110520413-A Big ring broad-spectrum antibiotic RQX PHARMACEUTICALS INC 2019-11-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198316-A9 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC PPARA 3021/4885SYK 2484/4885CTSS 93/4885
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC PPARA 3021/4885SYK 2484/4885CTSS 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.